How Long Does Semaglutide Take to Work?

The first injection is 0.25 mg, one-tenth of the full Wegovy dose. This is not a therapeutic dose for weight loss. It is a starter dose designed to let your gut adapt to GLP-1 receptor activation.

Within 24 to 72 hours, most people notice a shift. Food loses some of its pull. The mental chatter about what to eat next, sometimes called "food noise," gets quieter. You might eat half a sandwich and feel done. A meal that used to disappear in 10 minutes now takes 25.

Weight loss at this stage is modest: 1 to 4 pounds over the month, mostly from eating less rather than from metabolic changes. Some people lose nothing. That is normal. The 0.25 mg dose produces blood levels well below the threshold where the STEP trials measured significant weight loss (Blundell et al., Diabetes Obes Metab, 2022).

The most common side effect at this stage is nausea. It affects roughly 44% of users in clinical trials, though most describe it as mild. Eating smaller meals, avoiding greasy food, and staying hydrated reduces it substantially.

The dose doubles to 0.5 mg at week 5. This is where the shift becomes undeniable. Hunger signals dampen further. Cravings for high-calorie foods, especially sugar and fried food, weaken. Many people report that the psychological relationship with food changes: eating becomes functional rather than recreational.

Weight loss accelerates. The STEP 1 trial showed participants losing approximately 5% of body weight by week 8 (Wilding et al., NEJM, 2021). For a 220 lb person, that is 11 pounds. For a 180 lb person, roughly 9 pounds.

Gastric emptying slows noticeably at this dose. Food sits in the stomach longer, extending the feeling of fullness after meals. This is the mechanism behind both the appetite suppression and the GI side effects. If nausea was present at 0.25 mg, it often improves by week 5 because the body has adapted to GLP-1 stimulation. New nausea can appear briefly after the dose increase, then settle within a week.

The dose escalates to 1.0 mg at week 9 and 1.7 mg at week 13. This is the inflection zone. Weight loss that was gradual becomes visible. Faces look leaner. Waistbands loosen. People who have not seen you in a few weeks start commenting.

By week 12, average weight loss in the STEP trials reached 8 to 10% of starting body weight. Metabolic markers shift: fasting blood glucose drops, triglycerides fall, blood pressure improves. For people with type 2 diabetes, HbA1c reductions of 1.0 to 1.5 percentage points are typical at these doses (Davies et al., Lancet, 2021).

Fatigue can appear during this phase. It is usually caloric, not pharmacological. When you eat 500 to 800 fewer calories per day, energy dips are expected. Ensuring adequate protein intake (0.7 to 1.0 g per pound of lean body mass) and not skipping meals prevents most of it.

This is also when hair thinning can start. Rapid weight loss triggers telogen effluvium, a temporary shedding that peaks 2 to 4 months after the weight loss begins. The hair loss is caused by the caloric deficit, not the drug molecule itself.

The final escalation to 2.4 mg occurs at week 17 for Wegovy. This is the dose used in the STEP clinical trials. Appetite suppression is at its strongest. Most users report that hunger is no longer a meaningful obstacle. The challenge shifts from resisting food to remembering to eat enough.

Steady-state blood levels are reached approximately 4 to 5 weeks after starting any given dose. At 2.4 mg, steady state arrives around week 21 to 22. This means the full pharmacological effect is not achieved until roughly 5 months after the first injection.

At week 20, average weight loss in STEP 1 was approximately 12 to 13% of starting body weight. But the trajectory is still declining. The drug continues working for months beyond this point.

Weight loss continues throughout the first year and beyond. The STEP 1 trial, the largest semaglutide weight loss trial, ran for 68 weeks (about 16 months). At the endpoint, participants on 2.4 mg semaglutide lost an average of 14.9% of body weight, compared to 2.4% in the placebo group (Wilding et al., NEJM, 2021).

The rate of loss slows after month 6. This is not a plateau in the traditional sense. It is the body reaching a new equilibrium where caloric intake (reduced by semaglutide) matches caloric expenditure (reduced by lower body weight). The drug is still working. The math has simply rebalanced.

The STEP 5 trial extended treatment to 104 weeks (2 years) and found that weight loss was maintained, with an average of 15.2% total body weight reduction at the endpoint (Garvey et al., Nat Med, 2022). Longer treatment did not produce dramatically more weight loss, but it prevented regain.

Heavier individuals tend to lose more total pounds but a similar percentage of body weight. A person starting at 300 lbs might lose 45 lbs (15%) while a person starting at 180 lbs loses 27 lbs (15%). The absolute number differs, but the metabolic impact is comparable. Higher starting weights also produce faster initial losses because the caloric deficit created by reduced appetite is proportionally larger when baseline intake is higher.

People with type 2 diabetes or significant insulin resistance tend to lose weight more slowly on semaglutide. The STEP 2 trial (semaglutide in type 2 diabetes) showed 9.6% weight loss at 68 weeks, compared to 14.9% in the non-diabetic STEP 1 population (Davies et al., Lancet, 2021). Insulin resistance impairs the body's ability to mobilize fat stores. The drug still works, but results take longer to become visible. Blood sugar improvements, however, often appear within the first 4 weeks.

Semaglutide reduces how much you eat. It does not control what you eat. People who prioritize protein (0.7 to 1.0 g per pound of lean body mass) lose more fat and less muscle. Those who eat low-protein, high-carb diets despite reduced portions lose weight on the scale but sacrifice muscle mass, which slows metabolism and increases the likelihood of regain after stopping. For strategies to optimize nutrition on semaglutide, see our guide on not losing weight on semaglutide.

Exercise accelerates fat loss and preserves lean mass during semaglutide treatment. The STEP 3 trial added intensive behavioral therapy (including structured exercise) to semaglutide 2.4 mg. Participants lost 16.0% of body weight at 68 weeks, compared to 14.9% with semaglutide alone (Wadden et al., JAMA, 2021). Resistance training is particularly valuable because semaglutide-induced caloric deficits can accelerate muscle loss in sedentary users.

Some people are "super responders" who lose 20% or more of body weight. Others plateau at 8 to 10%. Genetic variation in GLP-1 receptor density, gut motility, and appetite-regulating circuits explains much of this spread. There is no way to predict your response before starting. The first 8 weeks give the best early signal: people who lose 5% or more by week 8 tend to achieve the best long-term results.

Certain medications counteract semaglutide's weight loss effects. Insulin, sulfonylureas, and some antidepressants (mirtazapine, olanzapine) promote weight gain through independent pathways. Beta-blockers reduce metabolic rate. If you are taking any of these, weight loss may be slower and total loss may be lower. Discuss alternatives with your prescriber rather than increasing the semaglutide dose beyond the recommended schedule. Check potential interactions with our peptide interaction checker.

Appetite suppression is the earliest effect and the most reliable sign the drug is active. By day 3 to 5 after the first injection, most users notice reduced hunger between meals, smaller portion satisfaction, and less preoccupation with food. At 0.25 mg, this effect is subtle. At 1.0 mg and above, it becomes dominant. Many users describe it as the absence of a signal rather than the presence of one: you simply stop thinking about food between meals.

The STEP 1 study included food craving questionnaires. Participants on semaglutide reported 15 to 25% reductions in craving intensity for sweet, savory, and high-fat foods compared to placebo (Blundell et al., Diabetes Obes Metab, 2022). This effect strengthened with dose increases and persisted at 68 weeks.

For people with type 2 diabetes, fasting glucose improvements appear within 1 to 2 weeks. HbA1c, which reflects average blood sugar over 3 months, shows meaningful reductions by week 8 to 12. The SUSTAIN trials documented HbA1c reductions of 1.5 to 1.8 percentage points at the 1.0 mg dose (Ahren et al., Lancet Diabetes Endocrinol, 2017).

Even in non-diabetic users, fasting insulin levels decrease as weight drops, indicating improved insulin sensitivity. Triglycerides fall by 12 to 20%. LDL cholesterol drops modestly. These changes are secondary to weight loss and typically become measurable after 8 to 12 weeks.

Systolic blood pressure decreases by 3 to 6 mmHg on average over 68 weeks of treatment. The SELECT trial, which studied semaglutide 2.4 mg in 17,604 overweight adults with cardiovascular disease, found a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) compared to placebo (Lincoff et al., NEJM, 2023). Blood pressure improvements typically become measurable after 12 to 16 weeks.

The relationship between semaglutide and energy is biphasic. During the first 4 to 8 weeks, fatigue is common because the body adjusts to lower caloric intake. After 8 to 12 weeks, most users report improved energy as excess weight decreases, sleep quality improves (especially if sleep apnea was present), and blood sugar stabilizes. Mood improvements are reported frequently, though the mechanism is debated: some is likely from weight loss itself, some from improved metabolic health, and some potentially from direct central GLP-1 receptor effects.